CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FiercePharma
Original article

{"a":[{"_":"Bayer offloads cancer drug Stivarga to Grünenthal for up to $431M as new competition looms","$":{"href":"/pharma/bayer-offloads-cancer-drug-stivarga-grunenthal-431m-new-competition-looms","hreflang":"en"}}]}

StivargaNegative
AI Analysis

Summary

Bayer is divesting its cancer drug Stivarga to Grünenthal for up to $431M as competition from Exelixis nears an FDA decision. The transaction reflects Bayer's strategic repositioning ahead of potential competitive pressure.

Outcome Details

Bayer offloading Stivarga to Grünenthal for up to $431M

Importance:6/10
Sentiment:
-0.30
asset divestiturecompetitioncancer drugFDA decision pending
Related Companies

Read the original article

Published by FiercePharma on September 21, 2026 10:00 AM

Read Original